The role of statins in vascular disease

European Journal of Vascular and Endovascular Surgery

Volumn 27, Issue 1, 2004, Pages 6-16

  Laws, P E ^a   Spark, J I ^a   Cowled, P A ^a   Fitridge, R A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Atherosclerosis; Ischaemia reperfusion injury; Statins; Vascular disease

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ANEURYSM; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIA; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPERFUSION INJURY; REVIEW; RISK FACTOR; STROKE; VASCULAR DISEASE; VEIN OCCLUSION;

EID: 0347525823     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2003.09.014     Document Type: Article

References (129)

1. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976; 29: 1346-1348.
2. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-1582.
3. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.
4. Goldstein JL, Brown MS. Lipoprotein receptors and the control of plasma LDL cholesterol levels. Eur Heart J 1992; 13: 34-36.
5. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33.
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
7. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221-225.
8. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629-635.
9. Nakai K, Suzuki Y, Kihira H, Wada H, Fujioka M, Ito M et al. Regulation of myosin phosphatase through phosphorylation of the myosin-binding subunit in platelet activation. Blood 1997; 90: 3936-3942.
10. Gonzalez-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: selectins and integrins. Crit Rev Immunol 1999; 19: 389-429.
11. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514.
12. van Nieuw Amerongen GP, van Hinsbergh VW. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001; 21: 300-311.
13. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358.
14. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-1500.
15. Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997; 95: 5-7.
16. Aengevaeren WR, Uijen GJ, Jukema JW, Bruschke AV, van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1997; 96: 429-435.
17. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-125A.
18. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
19. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164-176.
20. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
22. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
23. Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992; 107: 745-749.
24. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
25. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium inter-actions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1652-1659.
26. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
27. Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991; 83: 2012-2020.
28. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
29. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-31729.
30. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-8885.
31. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normo-cholesterolemic animals. Nat Med 2000; 6: 1004-1010.
32. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
33. 2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999; 34: 95-101.
34. Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 1997; 18: 231-240.
35. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
36. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139-1148.
37. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K et al. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994; 153: 2052-2063.
38. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-1199.
39. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
40. Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 1999; 145: 1293-1307.
41. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-1217.
42. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
43. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone Jr MA et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21: 1165-1171.
44. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-2900.
45. Dunzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997; 81: 963-969.
46. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
47. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
48. Oemar BS, Yang Z, Luscher TF. Molecular and cellular mechanisms of atherosclerosis. Curr Opin Nephrol Hypertens 1995; 4: 82-91.
49. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA. The dual role of mevalonate in the cell cycle. J Biol Chem 1983; 258: 378-385.
50. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137: S101-S109.
51. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539-545.
52. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
53. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996; 23: 755-765. discussion 765-766.
54. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 1993; 87: 1179-1187.
55. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791.
56. Gronholdt ML. Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the carotid artery. Arterioscler Thromb Vasc Biol 1999; 19: 2-13.
57. Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938-1944.
58. Loftus IM, Naylor AR, Bell PR, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002; 89: 680-694.
59. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
60. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678.
61. Opper C, Clement C, Schwarz H, Krappe J, Steinmetz A, Schneider J et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 1995; 113: 211-217.
62. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
63. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2442-2449.
64. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-272.
65. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
66. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112-116.
67. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-562.
68. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-116.
69. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002; 135: 284-292.
70. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
71. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
72. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
73. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
74. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
75. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
76. Pekkanen J, Tervahauta M, Nissinen A, Karvonen MJ. Does the predictive value of baseline coronary risk factors change over a 30-year follow-up? Cardiology 1993; 82: 181-190.
77. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001; 173: 139-143.
78. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 1994; 72: 128-132.
79. Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke 1991; 22: 1485-1490.
80. Norgren L. Life expectancy for critical limb ischaemia. London: WB Saunders, 1999.
81. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346: 1647-1653.
82. Multiple Risk Factor Intervention Trial Research Group, Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
83. Wolf PA, Kannel WB, Verter J. Current status of risk factors for stroke. Neurol Clin 1983; 1: 317-343.
84. Atkins D, Psaty BM, Koepsell TD, Longstreth Jr WT, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119: 136-145.
85. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155: 50-55.
86. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128: 89-95.
87. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-950.
88. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99: 216-223.
89. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97: 1784-1790.
90. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112-1120.
91. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999; 84: 1192-1197.
92. Callahan A. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol 2001; 88: 33J-37J.
93. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr. SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
94. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-453.
95. European Carotid Surgery Trialists' Collaborative Group, MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991; 337: 1235-1243.
96. Crouse III JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-459.
97. Pitsavos CE, Aggeli KI, Barbetseas JD, Skoumas IN, Lambrou SG, Frogoudaki AA et al. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1998; 82: 1484-1488.
98. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331: 1474-1479.
99. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2000; :CD000123.
100. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333-335.
101. Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998; 17: 335-340.
102. Rudich SM, Mongini PK, Perez RV, Katznelson S. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant Proc 1998; 30: 992-995.
103. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550-557.
104. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
105. Katznelson S. The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Contrib Nephrol 1997; 120: 97-104.
106. Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother 1997; 31: 489-491.
107. Statin therapy-what now? Drug Ther Bull 2001; 39: 17-21.
108. Wijesinghe LD, Gamage L, Berridge DC, Scott DJ. Measuring serum total cholesterol: do vascular surgeons know what they are doing? Ann R Coll Surg Engl 1999; 81: 32-36.
109. Evans J, Bhardwaj N, Loftus IM, Thompson MM. Management of intermittent claudication (Br J Surg; 89: 529-31). Br J Surg 2002; 89: 1323. author reply 1324-1325.
110. Shearman CP. Management of intermittent claudication. Br J Surg 2002; 89: 529-531.
111. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56: 53-56.
112. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer III DM, Trocha SD et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001; 103: 2598-2603.
113. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100: 178-184.
114. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13: 2288-2298.
115. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002; 22: 1567-1572.
116. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36: 150-157.
117. Christenson JT. Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovasc Surg 2001; 9: 33-43.
118. Suarez BK. Honolulu Heart Study: review of genetic analyses. Prog Clin Biol Res 1984; 147: 105-116.
119. Watt HC, Law MR, Wald NJ, Craig WY, Ledue TB, Haddow JE. Serum triglyceride: a possible risk factor for ruptured abdominal aortic aneurysm. Int J Epidemiol 1998; 27: 949-952.
120. Newman KM, Jean-Claude J, Li H, Ramey WG, Tilson MD. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 1994; 90: II224-II227.
121. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137: 1199-1213.
122. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96: 318-326.
123. Newman KM, Malon AM, Shin RD, Scholes JV, Ramey WG, Tilson MD. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 1994; 30: 265-276.
124. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999; 29: 122-127. discussion 127-129.
125. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-999.
126. Ebrahim S. Cost-effectiveness of stroke prevention. Br Med Bull 2000; 56: 557-570.
127. Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm 1999; 56: 1726-1732.
128. Buller N, Gillen D, Casciano R, Doyle J, Wilson K. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003; 21: 25-32.
129. Freemantle N, Hill S. Medicalisation, limits to medicine, or never enough money to go around? BMJ 2002; 324: 864-865.